Rezolute (Rezolute) Risk Assessment

View and export this data going back to 2011. Start your Free Trial

What is Rezolute Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Rezolute is: No Data: Cannot be evaluated.

Competitive Comparison of Rezolute's Risk Assessment

For the Biotechnology subindustry, Rezolute's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rezolute's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rezolute's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Rezolute's Risk Assessment falls into.

Rezolute (NAS:RZLT) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Rezolute Risk Assessment Related Terms

Thank you for viewing the detailed overview of Rezolute's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Rezolute (Rezolute) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rezolute Inc (NAS:RZLT) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

275 Shoreline Drive, Suite 500, Redwood City, CA, USA, 94065

Website

https://www.rezolutebio.com

Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.

Executives

Brian Kenneth Roberts	officer: Chief Medical Officer	C/O REZOLUTE, INC., 201 REDWOOD SHORES PARKWAY, SUITE 315, REDWOOD CITY CA 94065
Gil M Labrucherie	director	150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Wladimir Hogenhuis	director	60 LEVERONI COURT, NOVATO CA 94949
Nerissa Kreher	director	C/O AVROBIO, INC., ONE KENDALL SQ., BLDG. 300, STE. 201, CAMBRIDGE MA 02139
Handok, Inc.	10 percent owner	132, TEHERAN-RO, GANGNAM GU, SOUL M5 06235
Philippe Fauchet	director	C/O REZOLUTE, INC., 201 REDWOOD SHORES PARKWAY, SUITE 315, REDWOOD CITY CA 94065
Junghee Lim	director	C/O REZOLUTE, INC., 201 REDWOOD SHORE'S PARKWAY, SUITE 315, REDWOOD CITY CA 94065
Genexine Inc.	10 percent owner	700 DAEWANGPANGYO-RO, KOREA PARKBLDG. B, BUNDANG-GU, SEONGNAM-SI, GYEONGGI-DO M5 13488
Seline E. Miller	officer: VP Finance & CAO	C/O REZOLUTE, INC., 1450 INFINITE DRIVE, LOUISVILLE CO 80027
Young-jin Kim	director	49, BONGEUNSA-RO 49-GIL, GANGNAM-GU, SEOUL M5 06100
Young Chul Sung	director	101DONG 404HO, PARKTOWER APT. 69, SEOBINGGO-RO, YONGSAN-GU, SEOUL M5 04385
Keith A. Vendola	officer: Chief Financial Officer	111 LIVORNO WAY, REDWOOD CITY CA 94065
Xoma Corp	10 percent owner	2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
David F Welch	director	C/O INFINERA CORPORATION, 140 CASPIAN COURT, SUNNYVALE CA 94089
Morgan Fields	officer: Chief Accounting Officer	890 SANTA CRUZ AVE., MENLO PARK CA 94025